Please be on the look out for
Ambry Representatives at :
ASCO Breast Cancer Symposium 2014
Enhancing Clinical Care Through Collaboration
San Francisco, CA
09/4/14 - 09/6/14
Starting on June 26, 2013, Ambry Genetics will no longer accept cardiovascular NGS panels for testing. Suspended tests include: Brugada syndrome, Long QT syndrome, Arrhythmia, DCM, HCM, Cardiomyopathy and Pan Cardio panels. We will still be offering testing for Marfan, Aneurysm and Related Disorders, and Familial Hypercholesterolemia. In the future, we plan to release updated versions of cardiovascular NGS panels for testing with the addition of deletion/duplication analysis.
To better serve the growing needs of clinicians and patients, Ambry Genetics has expanded its cardiovascular genetics test offerings. We now offer multiple gene panels for hereditary cardiovascular diseases, including cardiomyopathies and arrhythmias.
Ambry’s new Pan Cardio Panel includes 79 genes that have been implicated in multiple cardiovascular diseases. Ambry also offers several smaller panels that include subsets of genes from the Pan Cardio Panel. These panels may be more specific to a particular person’s phenotype or clinical findings.